Summary
Johnson & Johnson (JNJ) filed an 8-K on October 18, 2005, to report its financial results for the third quarter ended October 2, 2005. The filing primarily includes a press release detailing the company's sales and earnings performance for the period. Investors should note that this report serves as a notification of the release of these financial figures, with the detailed information contained within the attached press release and supplementary financial data. This 8-K is important as it provides a snapshot of JNJ's operational and financial health during Q3 2005, enabling investors to assess the company's performance against expectations and prior periods. The attached exhibits are crucial for a thorough understanding of sales trends, profitability, and any significant financial developments that may impact the company's valuation and future outlook.
Key Highlights
- 1JNJ filed an 8-K on October 18, 2005, reporting Q3 2005 financial results.
- 2The report's primary purpose is to announce sales and earnings for the third quarter ended October 2, 2005.
- 3Key financial details are provided via an attached press release (Exhibit 99.15).
- 4Unaudited comparative supplementary sales data and condensed consolidated statements of earnings for Q3 are also included as Exhibit 99.20.
- 5The filing signifies the public release of JNJ's latest financial performance metrics.
- 6Investors can use this information to evaluate the company's recent financial health and operational progress.